Cerus Corporation
NASDAQ:CERSMedical - Devices
+$0.08 today
- Market cap
- $383.71M
- Beta
- 1.77
- P/E (TTM)
- -53.8
- EPS (TTM)
- -$0.05
Volume 6.69M
Average 2.33M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Cerus Corporation
NASDAQ:CERS
Intrinsic Alpha fair value
Locked
Current Price
$1.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +8.4% | +12.2% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Recent growth has been strongest in Revenue at +8.4% over three years. Forward estimates point to Revenue at +12.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Grifols, S.A. NASDAQ:GRFS | $7.35B | $8.69 | Not rated | 14.7 | -2.73% |
Haemonetics Corporation NYSE:HAE | $5.60B | $122.94 | Undervalued | 34.9 | +60.24% |
ADMA Biologics, Inc. NASDAQ:ADMA | $3.03B | $13.68 | Overvalued | 12.1 | -18.46% |
Continue the stock analysis
Jump to another research area for this company.